This new class of weight loss drugs are costly - but is there a greater price to ignoring the problem?

Christina Farr is a healthcare writer and investor. Formerly at CNBC and Reuters, she covers digital health, startups, and policy, blending reporting with analysis and investing perspective to help leaders navigate healthcare’s evolving landscape.

New York City